Aritra Ghosh

Mr. Aritra Ghosh

Computer Science, Florida Atlantic University, Boca Raton, Florida, USA
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 December 2023 in Information
Verified
Journal Article
Open access
PDF file
Aritra GhoshAritra Ghosh
Aritra Ghosh
MLMaria Mercedes Larrondo-Petrie
Maria Mercedes Larrondo-Petrie
MPMirjana Pavlovic
Mirjana Pavlovic
The evolvement of COVID-19 vaccines is rapidly being revolutionized using artificial intelligence-based technologies. Small compounds, peptides, and epitopes are collected to develop new therapeutics. These substances can also guide artificial intelligence-based modeling, screening, or creation. Machine learning techniques are used to leverage pre-existing data for COVID-19 drug detection and vaccine advancement, while artificial intelligence-based models are used for these purposes. Models based on artificial intelligence are used to evaluate and recognize the best candidate targets for future therapeutic development. Artificial intelligence-based strategies can be used to address issues with the safety and efficacy of COVID-19 vaccine candidates, as well as issues with manufacturing, storage, and logistics. Because antigenic peptides are effective at eliciting immune responses, artificial intelligence algorithms can assist in identifying the most promising COVID-19 vaccine candidates. Following COVID-19 vaccination, the first phase of the vaccine-induced immune response occurs when major histocompatibility complex (MHC) class II molecules (typically bind peptides of 12–25 amino acids) recognize antigenic peptides. Therefore, AI-based models are used to identify the best COVID-19 vaccine candidates and ensure the efficacy and safety of vaccine-induced immune responses. This study explores the use of artificial intelligence-based approaches to address logistics, manufacturing, storage, safety, and effectiveness issues associated with several COVID-19 vaccine candidates. Additionally, we will evaluate potential targets for next-generation treatments and examine the role that artificial intelligence-based models can play in identifying the most promising COVID-19 vaccine candidates, while also considering the effectiveness of antigenic peptides in triggering immune responses. The aim of this project is to gain insights into how artificial intelligence-based approaches could revolutionize the development of COVID-19 vaccines and how they can be leveraged to address challenges associated with vaccine development. In this work, we highlight potential barriers and solutions and focus on recent improvements in using artificial intelligence to produce COVID-19 drugs and vaccines, as well as the prospects for intelligent training in COVID-19 treatment discovery.

1 April 2019
Verified
Conference Paper
Closed access
Aritra GhoshAritra Ghosh
Aritra Ghosh
SHShihong Huang
Shihong Huang
Co-adaptive system is a close coupling between human and software system cooperating to achieve shared goals. This co-adaption requires adaptive actions to react to unpredictable circumstances. One of the challenges is to deal with uncertainties, and consequently, decision making under uncertainty, which may arise because of the change in the environment, the unpredictable resources, etc. Human behavior does contribute to large amounts of uncertainty. This paper presents an approach for using a simulator as a means of feedback to a human’s decision under uncertainty that can assist human in automated planning to generate cooperative and symbiotic strategy of human and the system to achieve given tasks. To validate the approach, this paper presents a customizable traffic simulator to measure the delays associated with passing vehicles through intersections. The simulator contains AI-based self-adaptive vehicles which can evaluate the quality of traffic at an intersection and change their driving behavior. The human operator from the outside of the system can manipulate the signaling time, the number of predicates per driving rule, number of rules per rule set, learning factor (adaption) etc. to overcome any unexpected traffic. This research proves that our simulator is more efficient than the individual human-operated and automated traffic system and makes a true cooperative traffic example.

15 July 2022 in International Journal of Darshan Institute on Engineering Research and Emerging Technologies
Verified
Journal Article
Closed access
Aritra GhoshAritra Ghosh
Aritra Ghosh

9 November 2023 in Preprints.org
Verified
Preprint
Open access
PDF file
Aritra GhoshAritra Ghosh
Aritra Ghosh
MLMaria Mercedes Larrondo-Petrie
Maria Mercedes Larrondo-Petrie
MPMirjana Pavlović
Mirjana Pavlović
AI-based approaches are increasingly being used to revolutionize vaccine development for COVID-19. Small molecules, peptides, and epitopes are being collected for therapy discovery, which could also direct AI-based models, screening, or generation [1]. AI-based models are being used for drug discovery and vaccine development, and pre-existing data is being leveraged through machine learning approaches for COVID-19 drug discovery and vaccine development [1]. The best candidate targets for future treatment development are being identified and evaluated using AI-based models [1]. AI-based approaches can be used to overcome challenges in manufacturing, storage, logistics, and safety and efficacy issues related to different vaccine candidates for COVID-19 [2]. AI algorithms can help identify the best vaccine candidates for COVID-19 while considering the efficiency of antigenic peptides for immune response generation [2]. The presentation of antigenic peptides by major histocompatibility complex (MHC) class II molecules is the first step after COVID-19 vaccine administration for any vaccine-induced immune response [2]. Thus, AI-based models are being used to identify the best vaccine candidates for COVID-19 and to ensure that the vaccine-induced immune response is efficient and safe. The utilization of AI-based methods to address logistical, manufacturing, storage, safety, and efficacy issues regarding several COVID-19 vaccine candidates will be examined in this study. Additionally, while considering the effectiveness of antigenic peptides for the induction of an immune response, we will determine the best potential targets for the next treatment development and assess how AI-based models can help discover the best vaccine candidates for COVID-19. This research ultimately intends to offer insights into how AI-based techniques can transform COVID-19 vaccine development and how they can be applied to address vaccine development issues. In this paper, we focus on recent advances in using artificial intelligence to develop COVID-19 drugs and vaccines, as well as the potential of intelligent training in discovering COVID-19 therapeutics, highlighting potential challenges and solutions.

1 April 2018
Verified
Conference Paper
Closed access
Aritra GhoshAritra Ghosh
Aritra Ghosh
SHShihong Huang
Shihong Huang
Software systems now can replace a vast amount of human resources with their quasi-autonomous features. Adaptive nature helps the system to adjust their behavior in response to their environmental changes. Most of these changes are unknown which put the system under uncertainty while making decisions. Decision-making in the real-time environment requires through observation for searching and analyzing different features of the environment in which the systems are running to understand how humans select relevant information. In this way, a human and a software system can jointly evaluate the situations and make the decision. Earlier visual search (VS) models believe that the eyes move to locations with maximum saliency and every eye movement is planned. It is hard to choose any optimal searching process when the operating characteristics of any visual system vary over time. Furthermore, this method does not account how the brain coordinates its different regions to process information over time. To address these limitations, we propose visual process as an instance of deep reinforcement learning which represents a step towards building autonomous systems to understand the visual world more accurately. In this paper, we begin with different visual search algorithms, including reinforcement learning, followed by probabilistic sequential decision making. In parallel, we focus on various existing areas of related research and their advantages and drawbacks within the domain. Finally, we propose a model which can address the shortcomings of the existing algorithms.

27 November 2023 in Preprints.org
Verified
Preprint
Open access
PDF file
Aritra GhoshAritra Ghosh
Aritra Ghosh
MPMirjana Pavlovic
Mirjana Pavlovic
MLMaria Mercedes Larrondo-Petrie
Maria Mercedes Larrondo-Petrie
The COVID-19 pandemic has significantly impacted global health and economies, necessitating the development of effective vaccines against the novel virus. Understanding the structure and function of SARS-CoV-2 is crucial for rational vaccine design. The virus consists of several key proteins, including the spike protein, envelope protein, membrane protein, and nucleocapsid protein. The spike protein plays a crucial role in host cell entry by binding to the angiotensin-converting enzyme 2 (ACE2) receptor on human cells. The replication of the virus within host cells is facilitated by various viral proteins, such as the RNA-dependent RNA polymerase (RdRp) and the main protease (Mpro). Rational vaccine design strategies for SARS-CoV-2 primarily focus on targeting the spike protein due to its role in host cell entry. However, developing vaccines against this protein is challenging due to its highly mutable nature and potential conformational changes. Alternative strategies involve using other viral proteins, such as the nucleocapsid protein, which is conserved and essential for viral replication. Considering T-cell responses in vaccine design is also vital as they play a vital role in controlling viral infections. Vaccines that elicit both antibody and T-cell responses are more likely to provide robust and durable immunity against SARS-CoV-2. Advancements in rational vaccine design for SARS-CoV-2 include mRNA-based vaccines, viral vector-based vaccines, and protein subunit vaccines. However, challenges remain in developing a universally effective vaccine, including the emergence of new SARS-CoV-2 variants and mutations that may affect the efficacy of existing vaccines. In conclusion, rational vaccine design for SARS-CoV-2 requires a comprehensive understanding of the virus's structure and function, targeting key viral proteins, and considering T-cell responses.